Beam Therapeutics annual total assets
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Total Assets Growth & History (BEAM)
Beam Therapeutics's total assets was $1.48B for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.48B | $377.4M | +34.19% |
| 2024 | 2024-12-31 | $1.10B | −$355.9M | −24.38% |
| 2023 | 2023-12-31 | $1.46B | $118.0M | +8.79% |
| 2022 | 2022-12-31 | $1.34B | −$132.7M | −9.00% |
| 2021 | 2021-12-31 | $1.47B | $1.02B | +226.44% |
| 2020 | 2020-12-31 | $451.7M | $295.6M | +189.35% |
| 2019 | 2019-12-31 | $156.1M | — | — |
Beam Therapeutics quarterly total assets
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.39B | −$4.8M | −0.35% |
| Q1 2026 | 2026-03-31 | $1.48B | $13.9M | +0.95% |
| Q4 2025 | 2025-12-31 | $1.48B | $377.4M | +34.19% |
| Q3 2025 | 2025-09-30 | $1.31B | $139.7M | +11.93% |
| Q2 2025 | 2025-06-30 | $1.39B | $129.9M | +10.30% |
| Q1 2025 | 2025-03-31 | $1.47B | $107.1M | +7.88% |
| Q4 2024 | 2024-12-31 | $1.10B | −$355.9M | −24.38% |
| Q3 2024 | 2024-09-30 | $1.17B | −$119.2M | −9.23% |
| Q2 2024 | 2024-06-30 | $1.26B | −$92.6M | −6.84% |
| Q1 2024 | 2024-03-31 | $1.36B | $27.4M | +2.06% |
| Q4 2023 | 2023-12-31 | $1.46B | $118.0M | +8.79% |
| Q3 2023 | 2023-09-30 | $1.29B | −$59.7M | −4.42% |
| Q2 2023 | 2023-06-30 | $1.35B | −$64.5M | −4.55% |
| Q1 2023 | 2023-03-31 | $1.33B | −$121.0M | −8.33% |
| Q4 2022 | 2022-12-31 | $1.34B | −$132.7M | −9.00% |
| Q3 2022 | 2022-09-30 | $1.35B | $193.7M | +16.75% |
| Q2 2022 | 2022-06-30 | $1.42B | $525.3M | +58.82% |
| Q1 2022 | 2022-03-31 | $1.45B | $760.2M | +109.65% |
| Q4 2021 | 2021-12-31 | $1.47B | $1.02B | +226.44% |
| Q3 2021 | 2021-09-30 | $1.16B | $878.3M | +315.62% |
| Q2 2021 | 2021-06-30 | $893.1M | $593.1M | +197.72% |
| Q1 2021 | 2021-03-31 | $693.2M | $370.6M | +114.87% |
| Q4 2020 | 2020-12-31 | $451.7M | $295.6M | +189.35% |
| Q3 2020 | 2020-09-30 | $278.3M | — | — |
| Q2 2020 | 2020-06-30 | $300.0M | — | — |
| Q1 2020 | 2020-03-31 | $322.6M | — | — |
| Q4 2019 | 2019-12-31 | $156.1M | — | — |
Beam Therapeutics total assets trends
Over the last five fiscal years, Beam Therapeutics's total assets increased from $451.7M to $1.48B, a change of $1.03B. The latest reported quarter, Q2 2026, shows $1.39B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...